NYU's Clasping Antibody Platform generates high-affinity, recombinant antibodies that use a unique cooperative binding mode to target challenging antigens, such as site-specific post-translational modifications. This technology provides highly specific, consistent, and renewable reagents for diagnostics and research, overcoming the limitations of traditional, animal-derived antibodies. NYU is seeking industry partners for commercialization.
The Clasping Antibody Platform is a synthetic technology developed by New York University researchers to produce high-performance recombinant antibodies capable of targeting challenging antigens, particularly site-specific post-translational modifications (PTMs). By utilizing a unique, binding mode-guided approach known as antigen-clasping, two antigen-binding sites work cooperatively to sandwich a single antigen. This mechanism creates an extensive binding surface, resulting in high affinity and selectivity. This platform offers a superior alternative to traditional animal-derived antibodies, providing consistent, renewable reagents for research and diagnostic applications.
The technology is at a stage of lab validation and prototype demonstration (TRL 4-5). A suite of anti-PTM clasping antibodies has been functionally validated using techniques such as immunoprecipitation, biolayer interferometry, western blotting, and chromatin immunoprecipitation. NYU has filed a U.S. provisional patent application and is currently seeking an industry partner to support further commercialization and development.
New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.